Shares of Radius Health Inc (NASDAQ:RDUS) have received a consensus recommendation of “Hold” from the twelve brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $54.17.
A number of research firms have recently issued reports on RDUS. Maxim Group restated a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Cantor Fitzgerald restated a “buy” rating and set a $58.00 price target on shares of Radius Health in a report on Thursday. ValuEngine upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Citigroup restated a “hold” rating and set a $43.00 price target on shares of Radius Health in a report on Monday. Finally, BidaskClub lowered shares of Radius Health from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th.
Radius Health (NASDAQ:RDUS) traded up $0.48 during mid-day trading on Friday, hitting $38.50. 1,106,940 shares of the stock were exchanged, compared to its average volume of 998,473. Radius Health has a twelve month low of $24.66 and a twelve month high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. The firm has a market capitalization of $1,720.00, a price-to-earnings ratio of -7.09 and a beta of 1.10.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the company earned ($1.07) EPS. equities research analysts predict that Radius Health will post -5.62 EPS for the current fiscal year.
In related news, insider Jesper Hoiland acquired 6,800 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average cost of $29.04 per share, with a total value of $197,472.00. Following the completion of the transaction, the insider now owns 12,900 shares of the company’s stock, valued at approximately $374,616. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction that occurred on Wednesday, October 25th. The shares were bought at an average cost of $32.85 per share, for a total transaction of $1,642,500.00. Following the completion of the transaction, the insider now directly owns 5,548,799 shares of the company’s stock, valued at approximately $182,278,047.15. The disclosure for this purchase can be found here. Insiders have purchased 158,578 shares of company stock worth $4,659,916 over the last ninety days. 15.00% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new stake in Radius Health in the third quarter worth approximately $110,000. Ameritas Investment Partners Inc. grew its position in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. grew its position in Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank bought a new stake in Radius Health in the second quarter worth approximately $211,000. Finally, Principal Financial Group Inc. grew its position in Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.
WARNING: “Radius Health Inc (RDUS) Receives $52.00 Average PT from Brokerages” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/radius-health-inc-rdus-receives-52-00-average-pt-from-brokerages.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.